Oricell Therapeutics Presents Preclinical Data of BCMAxGPRC5D Dual-Target CAR-T Therapy at SITC 2024, Abstract Selected Among Top 100
Oricell Therapeutics
Developer of Tumor Immunocyte Products
Click on the image to register for free2025 IBI EXPO
November 13, 2024
eMedClub News
Shanghai, China, and New Jersey, USA (November 11, 2024) — Oricell Therapeutics, a clinical-stage biotechnology company focused on developing innovative cell therapies and committed to becoming a global leader in tumor immunotherapy innovation, announced that it delivered an oral presentation on November 9, 2024, at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) held in Houston, Texas, USA. The presentation featured preclinical study data of its dual-target BCMAxGPRC5D CAR-T therapy for heterogeneous multiple myeloma (MM). Additionally, the preclinical data abstract was selected as one of the SITC TOP 100 Abstracts.
2025 (3rd) Biopharmaceutical Innovation Industry Conference
Pre-registration Opened
Multiple myeloma is a complex and heterogeneous disease characterized by the presence of multiple myeloma plasma cells (MMPCs), which independently and highly express BCMA and GPRC5D antigens.Traditional single-target CAR-T therapies (such as BCMA-targeted CAR-T) have shown promising clinical outcomes, but the duration of treatment response is often limited due to antigen downregulation, loss, or shedding, leading to disease relapse.To overcome this limitation of the single-target CAR-T therapy, Qrigincell Therapeutics has introduced the BCMAxGPRC5D dual-target CAR-T therapy, which, together with OriCAR-017 in the clinical stage, demonstrates the company's comprehensive and in-depth development strategy in the field of multiple myeloma treatment.
This dual-target product integrates multiple highly sensitive and highly specific humanized antibody binding domains, targeting BCMA and GPRC5D antigens respectively, and incorporates the company's self-developed Ori technology, aiming to significantly enhance the anti-tumor activity of T cells. At this conference, Qrigincell Therapeutics reported preclinical research data on its BCMAxGPRC5D CAR-T therapy, with key highlights including:
Significantly enhanced anti-tumor activity, outperforming single-antigen CAR-T therapy in preclinical models, effectively eliminating various myeloma cells.
Enable CAR-T cells to better expand and persist under the pressure of high tumor burden.
Effectively addresses the issue of antigen loss, maintaining killing activity against tumor cells with any tumor antigen escape, overcoming the limitations of single-antigen therapy.
Preclinical studies also showed good tolerability.
Dr. He Xiaowen, Co-founder and Chief Scientific Officer of Qrigincell Therapeutics, stated: "The dual-target strategy has enabled us to create a more stable candidate product that is less susceptible to antigen escape, covering a large target population of patients with multiple myeloma, and is expected to provide new treatment hope for these patients. We are very much looking forward to advancing clinical validation as soon as possible."
"We are very excited that the BCMAxGPRC5D CAR-T therapy can enrich and expand the treatment options for multiple myeloma," said Yang Huanfeng, co-founder and CEO of Oricell Therapeutics Holdings Limited. "With its ability to address tumor heterogeneity and effectively prevent disease recurrence, we believe that BCMAxGPRC5D CAR-T therapy has the potential to become a new treatment option for patients with this refractory disease at all stages, adding significant value to the field of MM treatment."
About Oricell Therapeutics
Qrigincell Therapeutics is a clinical-stage biotechnology company dedicated to becoming an innovation-driven global leader in cancer immunotherapy. It currently focuses on developing innovative cell therapies to address unmet medical needs in the fields of global oncology and immunology. Through its self-developed Ori...®Ab Antibody Screening and Engineering Platform, Ori®Based on the CAR structural platform and expertise accumulated in the CMC field, Qrigincell Therapeutics has developed multiple product pipelines for the treatment of hematologic malignancies and solid tumors. These have demonstrated good safety and efficacy in exploratory clinical studies. Relevant clinical research data were published at international conferences such as the 2021 ASCO, 2022 ASCO, 2022 EHA, 2024 ASCO, 2024 SITC, as well as in the international academic journal *The Lancet Haematology*.
Welcome everyone to register for the 2025 IBI EXPO conference and keep pace with the times. Below is the 2024 IBI EXPO.Video Highlights of the Event.
Registration and Event Consultation
IBI EXPO 2025 (3rd) Biopharmaceutical Innovation Industry ConferenceWill beMarch 1-2, 2025InSuzhou International Expo CenterGrandly held. The theme of the conference isCollaboratively Building the Entire Chain, Innovating a New Ecosystem for Transformation。
The conference will invite300+Guest Speaker, Opening30+Forum events, covering hundreds of hot topics, aroundCell and Gene Therapy, Radiopharmaceuticals, Antibody Innovation Conjugation, Targeted Protein Degradation, Stem Cell Regeneration, mRNA Vaccines and Nucleic Acid Drugs, Exosomesetc.New Molecular Drugs,AI Drug Discovery, Organoids, Novel Delivery Vectorsetc.Cutting-edge Technology，Engage in exchange and discussion,联动Pharmaceutical companies, research institutions, clinical resources, supply chain enterprises, investment and financing institutions, park governmentsWith the efforts of multiple parties, cutting-edge innovations are being transformed from scientific research to industrial applications, injecting a source of development into the biopharmaceutical market.
Free Participation:Teacher Yang 15517201185
Free Exhibition:Teacher Yuan 15572286596
Speech & Media：Teacher Wang 18717836231
Exciting Live Broadcast Preview
Long press to scan the QR code and participate immediately ↓
DianDian "Share”、“Like" and "In View"，Give me a little recharge~"